Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
NCT ID: NCT00025727
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
330 participants
INTERVENTIONAL
2001-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lopinavir/Ritonavir
Ritonavir
GW433908
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a viral load of 1,000 or more copies/ml.
* Have taken protease inhibitors (PIs).
* Have taken PI drugs for at least 12 straight weeks and have had virologic failure on the PIs.
* Are now taking antiretroviral therapy.
* Are male or female and are at least 13 years old (or 18 if local requirement) and can provide consent from parent or guardian if under 18.
* Are females unable to have children or, if are able to have children, are not pregnant and agree to use approved birth control.
Exclusion Criteria
* Have taken APV or LPV for more than 1 week.
* Have taken tenofovir disoproxil fumarate (TDF) or adefovir.
* Have taken more than 2 PIs.
* Are unable to take 2 active RTIs, as specified by the study.
* Have an active CDC Category C disease.
* Have certain abnormal laboratory tests.
* Are pregnant or breast-feeding.
* Have a serious health problem (e.g., diabetes, heart problems, hepatitis) that might risk the safety of the patient.
* Have a history of significant kidney or bone disease.
* Are not able to take drugs by mouth and cannot absorb them.
* Have had pancreatitis or hepatitis within the previous 6 months.
* Have a drug allergy or other allergy which might cause a problem during the study.
* Have had radiation or chemotherapy within 28 days of taking the study drug, or expect to need these during the study.
* Have taken drugs that affect the immune system (corticosteroids, interleukins, interferons) or drugs with anti-HIV activity (hydroxyurea or foscarnet) within 28 days prior to taking the study drug.
* Have had any HIV vaccine within 3 months before taking the study drug.
* Have taken certain other drugs within 28 days prior to taking the study drug, or expect to need them during the study.
* Use alcohol or illicit drugs in a way that the doctor feels would interfere with the study.
* Are not able to take the study drugs.
* Have inadequate kidney function.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Body Positive
Phoenix, Arizona, United States
Ocean View Internal Medicine
Long Beach, California, United States
Bisher Akil
Los Angeles, California, United States
Tower ID Med Associates
Los Angeles, California, United States
Orange Coast Med Group
Newport Beach, California, United States
Pacific Horizons Med Group
San Francisco, California, United States
Denver Inf Disease Consultants
Denver, Colorado, United States
Physicans Home Service
Washington D.C., District of Columbia, United States
IDC Research Initiative
Altamonte Springs, Florida, United States
Bach and Godofsky
Bradenton, Florida, United States
Community Health Care
Fort Lauderdale, Florida, United States
Therafirst Med Ctr
Fort Lauderdale, Florida, United States
North Broward Hosp District / HIV Clinical Research
Fort Lauderdale, Florida, United States
Florida ID Group
Orlando, Florida, United States
Discovery Alliance Inc
Pensacola, Florida, United States
West Florida Clinical Research Ctr
Pensacola, Florida, United States
Med College of Georgia
Augusta, Georgia, United States
Rush Med College / Dept of Infectious Diseases
Chicago, Illinois, United States
Boston Med Ctr / Evans - 556
Boston, Massachusetts, United States
Abbott-Northwestern Hosp / Clinic 42
Minneapolis, Minnesota, United States
Southampton Healthcare Inc
St Louis, Missouri, United States
South Jersey Infectious Diseases Inc
Somers Point, New Jersey, United States
ID Care Inc
Somerville, New Jersey, United States
Garden State Infectious Diseases / E I P Kennedy Health Sys
Voorhees Township, New Jersey, United States
Gervais Frechette
New York, New York, United States
Duke Univ Med Ctr
Durham, North Carolina, United States
Summa Health System
Akron, Ohio, United States
Fanno Creek Clinic
Portland, Oregon, United States
Roger Williams Med Ctr
Providence, Rhode Island, United States
Methodist Healthcare
Memphis, Tennessee, United States
Joseph Gathe
Houston, Texas, United States
Virginia Commonwealth Univ
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
316C
Identifier Type: -
Identifier Source: org_study_id